## MDT: Medtronic plc - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -0.7% below STRENGTH zone (4.0-10.0%); PEG 3.69 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: declining volume (57% of avg), momentum weakening (-5.6% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($97.66)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 10, Bearish: 0)

**1. Medtronic PLC (NYSE:MDT) Declares Quarterly Dividend of $0.71**
- Source: MarketBeat | 20251205T125116 | Bullish | Relevance: 100%
- Medtronic PLC (NYSE:MDT) has declared a quarterly dividend of $0.71 per share, payable on January 16, 2026, to shareholders of record on December 26, 2025. This dividend represents a 2.8% yield and is supported by Medtronic's 49 consecutive years of dividend increases and a payout ratio around 47.2%. The medical technology company recently beat Q3 earnings expectations with $1.36 EPS and $8.96B revenue, and provided FY2026 EPS guidance of $5.62–$5.66.

**2. Medtronic plc declares $0.71 dividend**
- Source: MSN | 20251205T120833 | Bullish | Relevance: 100%
- Medtronic plc (NYSE: MDT) has declared a quarterly cash dividend of $0.71 per ordinary share. The dividend is payable on January 17, 2025, to shareholders of record at the close of business on December 27, 2024.

**3. Medtronic earns expanded FDA nod for deep brain stim**
- Source: MassDevice | 20251205T120653 | Bullish | Relevance: 100%
- Medtronic (NYSE: MDT) has announced that the FDA approved expanded labeling for its deep brain stimulation (DBS) offering, shifting from humanitarian device exemption (HDE) status to full effectiveness labeling. This approval extends the use of Medtronic's DBS technology to include dystonia, a movement disorder, making it the third-most common movement disorder in the U.S. The Percept platform, which delivers DBS, now includes adaptive capabilities with BrainSense technology, offering tailored, non-destructive treatment for adult and pediatric patients with various forms of dystonia.

**4. Medtronic (NYSE: MDT) declares $0.71 Q3 dividend, 48th year of increases**
- Source: Stock Titan | 20251204T213707 | Bullish | Relevance: 100%
- Medtronic (NYSE: MDT) has announced a cash dividend of $0.71 per share for the third quarter of fiscal year 2026, payable on January 16, 2026, to shareholders of record as of December 26, 2025. This declaration marks the 48th consecutive year of annual dividend increases for the company, affirming its status as an S&P 500 Dividend Aristocrat. The dividend aligns with the increase announced in May 2025, reflecting Medtronic's consistent financial performance and commitment to shareholder returns.

**5. Medtronic’s Hugo surgical robot earns FDA clearance**
- Source: MedTech Dive | 20251204T163310 | Bullish | Relevance: 100%
- Medtronic's Hugo surgical robot has received FDA clearance for urologic procedures in the U.S., positioning it as a significant challenger to Intuitive Surgical in the robotic surgery market. This authorization allows hospitals more choice in expanding their robotic programs, with plans to extend the robot's use to general surgery and gynecology in the future. The company anticipates this expansion will help revive growth in its medical/surgical portfolio and leverage its modular design and digital technologies as key differentiators.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 9, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-20 | Barclays | $111 | $109 | +2% |
| 2025-11-20 | Truist Securiti | $110 | $103 | +7% |
| 2025-11-19 | Morgan Stanley | $117 | $107 | +9% |
| 2025-11-19 | RBC Capital | $118 | $111 | +6% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-20 | Barclays | main | Overweight |
| 2025-11-20 | Truist Securiti | main | Hold |
| 2025-11-19 | Morgan Stanley | main | Overweight |
| 2025-11-19 | RBC Capital | main | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 6 ($0.53M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 43.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 9.9% (+0.1%)
- Blackrock Inc.: 9.3% (-2.4%)
- JPMORGAN CHASE & CO: 8.1% (+197.7%)
- State Street Corpora: 4.7% (+1.1%)
- Capital Research Glo: 2.4% (-15.6%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-5.6% 5d) with bearish MACD, trend may be turning.
2. Valuation stretched: PEG 3.7x requires aggressive growth execution.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Analyst target momentum: 9 raises (avg +11%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 3.69 signals overvaluation risk, limited margin of safety. Forward P/E 16.6x stretched relative to 8% growth. Balance sheet: strong liquidity (2.4x). Analyst sentiment positive (9 raises, avg +11%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $123.8B |
| Beta | 0.72 |
| 52W Range | $79.29 - $106.33 |
| Short Interest | 1.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.69 |
| Forward P/E | 16.6 |
| Current P/E | 17.9 |
| YoY Growth | 8.2% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 4.8% to -0.7% (-5.6% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 4.7pp (needs >4.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 58. Volume at 57% of 20MA suggests lack of conviction. OFD pattern: -MUL (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.74% (CS: 48) | Neutral |
| RSI_14 | 58.5 | Neutral |
| MACD Histogram | -0.04 | Bearish |
| vs SMA20 | 1.016x | Above |
| vs SMA50 | 1.049x | Above |
| vs SMA200 | 1.117x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $101.36
- **Stop Loss:** $97.66 (3.7% risk)
- **Target:** $105.06 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 135
- **Position Value:** $13,683.60
- **Portfolio %:** 13.68%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with balanced risk appetite. VIX near 15th percentile of 52-week range signals calm conditions, while modest yield curve steepening (54bps 10Y-3M) suggests healthy growth expectations. Breadth at 52% indicates selective participation rather than broad-based momentum.*

### Earnings

**Next:** 2026-02-17 (Est: $1.34)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q4 | $1.31 | $1.36 | +3.5% |
| 2025Q3 | $1.23 | $1.26 | +2.5% |
| 2025Q2 | $1.58 | $1.62 | +2.7% |
| 2025Q1 | $1.36 | $1.39 | +2.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*